| Business Summary | | ViroPharma
Incorporated
is
a
pharmaceutical
company
dedicated
to
the
commercialization,
development
and
discovery
of
new
antiviral
medicines.
The
Company
has
focused
its
current
product
development
and
discovery
activities
on
a
number
of
ribonucleic
acid,
or
RNA,
virus
diseases.
These
include
viral
respiratory
infection
(VRI),
often
referred
to
as
the
common
cold;
hepatitis
C;
and
respiratory
syncytial
virus
disease,
or
RSV
disease.
The
Company
currently
is
developing
its
most
advanced
product
candidate,
Picovir
(pleconaril),
for
the
treatment
of
common
diseases
caused
by
picornaviruses.
In
preclinical
studies,
Picovir
has
been
demonstrated
to
inhibit
picornavirus
replication
in
vitro
by
a
novel,
virus-
specific
mode
of
action.
Picovir
works
by
inhibiting
the
function
of
the
viral
protein
coat,
also
known
as
the
viral
capsid,
which
is
essential
for
virus
infectivity
and
transmission. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VPHM
is
engaged
in
the
discovery
and
development
of
proprietary
antiviral
pharmaceuticals
for
the
treatment
of
diseases
caused
by
RNA
viruses.
For
the
six
months
ended
6/30/01,
revenues
increased
67%
to
$2.5
million.
Net
loss
applicable
to
Common
totaled
$41.1
million,
up
from
$12.5
million.
Revenues
reflect
the
completion
of
two
large
phase
three
clinical
trials
with
Picovir.
Net
loss
reflects
costs
related
to
the
expansion
of
intellectual
property
rights
of
Picovir. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Claude Nash, Ph.D., 58 Chairman | $622K | $311.6K | Michel De Rosen, 50 Pres,
CEO, Director | 1.6M | -- | Vincent Milano, 37 CFO,
VP, Treasurer | 351K | 166.8K | Thomas Doyle, 40 VP,
Gen. Counsel and Sec. | 327K | 7.0K | Marc Collett, Ph.D., 49 VP
of Discovery Research | 417K | 58.4K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|